BioSpace News Archive

Seger Surgical Solutions Ltd. announced that it has launched development of its next generation laparoscopic stapler for intracorporeal anastomosis.

Nuvo Group—a privately-held company commercializing INVU™ by Nuvo™, an FDA-cleared, prescription-initiated remote pregnancy monitoring and management system, today announced a partnership with Charité – Universitätsmedizin Berlin, one of the largest university hospitals in Europe.

Nektar Therapeutics’ (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern Time.

Drug makers, biotech companies, biologics developers and CROs will now have the much-needed 21 CFR Part11-compliant software for their GatorPrime and GatorPlus Biolayer Interferometry systems (BLI).

Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, announced the appointment of Laurence Reid, Ph.D. to its board of directors.

DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chief Executive Officer and Chairman Flagg Flanagan will present at the 40th Annual J.P. Morgan Healthcare Conference.

The demand within the global arthroscopy devices market is set to increase by a dramatic chase in the times to follow.

The growing prevalence of coronary artery diseases stands as a key factor aiding in expansion of the global antisense and RNAi therapeutics market and is likely to continue so during the forecast period set between 2020 and 2030.

The advent of m-Health or mobile health has transformed the accessibility of patient care. While m-Health operates through mobile devices such as mobile phones and other smart communication devices for healthcare information delivery, development of mobile apps has almost brought the hospital to patient rather than the conventional care-approach flow from the patient to the hospital.

Oncopeptides AB, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, announces a financial update after the restructuring of the company, following the withdrawal of Pepaxto® from the US market.